Modulating T-cell costimulation as new immunosuppressive concept in organ transplantation

Current Opinion in Organ Transplantation

Volumn 17, Issue 4, 2012, Pages 368-375

  Pilat, Nina ^a   Schwarz, Christoph ^a   Wekerle, Thomas ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

belatacept; costimulation blockade; immunosuppression; organ transplantation

Indexed keywords

ABATACEPT; ABI 793; ALEFACEPT; ASKP 1240; BASILIXIMAB; BELATACEPT; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOSPORIN; EFALIZUMAB; INDOLEAMINE 2,3 DIOXYGENASE; IPILIMUMAB; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN BCL XL; RUPLIZUMAB; SIPLIZUMAB; STEROID; TGN 1412; TICILIMUMAB; TORALIZUMAB; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; CANCER THERAPY; CELL MIGRATION; CELL STIMULATION; CELL SURVIVAL; DRUG WITHDRAWAL; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MELANOMA; MULTIPLE ORGAN FAILURE; NEOPLASM; ORGAN TRANSPLANTATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PILOT STUDY; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; THROMBOEMBOLISM;

COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84864713203     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328355fc94     Document Type: Review

References (76)

1. Casey MJ, Meier-Kriesche HU. Calcineurin inhibitors in kidney transplantation: friend or foe? Curr Opin Nephrol Hypertens 2011; 20:610-615.
2. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the united states: A critical reappraisal. Am J Transplant 2010; 11:450-462.
3. Lafferty KJ, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 1975; 53:27-42.
4. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987; 165:302-319.
5. Pilat N, Sayegh MH, Wekerle T. Costimulatory pathways in transplantation. Sem Immunol 2011; 23:293-303.
6. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5:443-453.
7. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353:770-781.
8. Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010; 21:1587-1596.
9. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10:535-546.
10. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10:547-557.
11. Wekerle T, Grinyo JM. Belatacept: from rational design to clinical application. Transpl Int 2012; 25:139-150.
12. Pilat N, Wekerle T. Belatacept and Tregs: friends or foes? Immunotherapy 2012; 4:351-354.
13. Poirier N, Blancho G, Vanhove B. A more selective costimulatory blockade of the CD28-B7 pathway. Transpl Int 2011; 24:2-11.
14. Poirier N, Azimzadeh AM, Zhang T, et al. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med 2010; 2:17ra0.
15. Hodi FS, ODay SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
16. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3:611-618.
17. Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004; 13:391-397.
18. Kawai T, Andrews D, Colvin RB, et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000; 6:114.
19. Imai A, Suzuki T, Sugitani A, et al. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation 2007; 84:1020-1028.
20. Aoyagi T, Yamashita K, Suzuki T, et al. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. Am J Transplant 2009; 9:1732-1741.
21. Oura T, Yamashita K, Suzuki T, et al. Long-Term Hepatic Allograft Acceptance Based on CD40 Blockade by ASKP1240 in Nonhuman Primates. Am J Transplant 2012 [Epub ahead of print].
22. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345:248-255.
23. Weaver TA, Charafeddine AH, Agarwal A, et al. Alefacept promotes costimulation blockade based allograft survival in nonhuman primates. Nat Med 2009; 15:746-749.
24. Rostaing L, Mourad M, Charpentier B, et al. Efficacy and Safety of alefacept in combination with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation [Abstract]. Am J Transplant 2011; 11 (Suppl s2):98.
25. Bromberg JS, Cibrik D, Steinberg S, et al. A Phase 2 Study to Assess the Safety and Efficacy of Alefacept (ALEF) in De Novo Kidney Transplant Recipients [Abstract]. Am J Transplant 2011; 11 (Suppl s2):190.
26. Vincenti F, Mendez R, Pescovitz M, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 2007; 7:1770-1777.
27. Zhu Y, Yao S, Chen L. Cell surface signaling molecules in the control of immune responses: a tide model. Immunity 2011; 34:466-478.
28. Paterson AM, Vanguri VK, Sharpe AH. SnapShot: B7/CD28 costimulation. Cell 2009; 137:974-984.
29. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002; 2:116-126.
30. Boomer JS, Green JM. An enigmatic tail of CD28 signaling. Cold Spring Harb Perspect Biol 2010; 2:a002436.
31. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19:225-252.
32. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23:515-548.
33. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997; 7:445-450.
34. Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995; 3:87-98.
35. Linsley PS, Greene JL, Brady W, et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994; 1:793-801.
36. Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011; 332:600-603.
37. Hwang KW, Sweatt WB, Brown IE, et al. Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. J Immunol 2002; 169:633-637.
38. Yao S, Zhu Y, Zhu G, et al. B7-H2 is a costimulatory ligand for CD28 in human. Immunity 2011; 34:729-740.
39. Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27:111-122.
40. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174:561-569.
41. Lin H, Bolling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993; 178:1801-1806.
42. Baliga P, Chavin KD, Qin L, et al. CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity. Transplantation 1994; 58:1082-1090.
43. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381:434-438.
44. Wekerle T, Kurtz J, Bigenzahn S, et al. Mechanisms of transplant tolerance induction using costimulatory blockade. Curr Opin Immunol 2002; 14:592-600.
45. Linsley PS, Nadler SG. The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev 2009; 229:307-321.
46. Vondran FW, Timrott K, Kollrich S, et al. Decreased frequency of peripheral CD4-CD161-Th17-precursor cells in kidney transplant recipients on longterm therapy with Belatacept. Transpl Int 2012; 25:455-463.
47. Bouguermouh S, Fortin G, Baba N, et al. CD28 co-stimulation down regulates Th17 development. PloS One 2009; 4:e5087.
48. Bigenzahn S, Pratschke J, Koenigsrainer A, et al. Belatacept does not activate indoleamine 2,3-dioxygenase (IDO) in de novo liver transplant recipients. Am J Transplant 2011; s2:263-264. (abstract).
49. Tacke M, Hanke G, Hanke T, Hunig T. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur J Immunol 1997; 27:239-247.
50. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355:1018-1028.
51. Golovina TN, Mikheeva T, Suhoski MM, et al. CD28 costimulation is essential for human T regulatory expansion and function. J Immunol 2008; 181:2855-2868.
52. Ford ML, Larsen CP. Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol Rev 2009; 229:294-306.
53. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin: dependent mechanism. Nat Med 2002; 8:247-252.
54. Kirk A, Burkly L, Batty D, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5:686-693.
55. Kenyon NS, Fernandez LA, Lehmann R, et al. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes 1999; 48:1473-1481.
56. Law C, Grewal I. Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges. Adv Exp Med Biol 2009; 647:8-36.
57. Haanstra KG, Ringers J, Sick EA, et al. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 2003; 75:637-643.
58. Pearson TC, Trambley J, Odom K, et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002; 74:933-940.
59. Adams AB, Shirasugi N, Jones TR, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005; 174:542-550.
60. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997; 94:8789-8794.
61. Gilson CR, Milas Z, Gangappa S, et al. Anti-CD40 monoclonal antibody synergizes with CTLA4-Ig in promoting long-term graft survival in murine models of transplantation. J Immunol 2009; 183:1625-1635.
62. Pilat N, Wekerle T. Transplantation tolerance through mixed chimerism. Nat Rev 2010; 6:594-605.
63. Moingeon P, Chang HC, Sayre PH, et al. The structural biology of CD2. Immunol Rev 1989; 111:111-144.
64. Lo DJ, Weaver TA, Stempora L, et al. Selective targeting of human alloresponsive CD8-effector memory T cells based on CD2 expression. Am J Transplant 2011; 11:22-33.
65. Majeau GR, Meier W, Jimmo B, et al. Mechanism of lymphocyte functionassociated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 1994; 152:2753-2767.
66. Shapira MY, Abdul-Hai A, Resnick IB, et al. Alefacept treatment for refractory chronic extensive GVHD. Bone Marrow Transplant 2009; 43:339-343.
67. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358:353-361.
68. Nicolls MR, Gill RG. LFA-1 (CD11a) as a therapeutic target. Am J Transplant 2006; 6:27-36.
69. Owens T. A role for adhesion molecules in contact-dependent T help for B cells. Eur J Immunol 1991; 21:979-983.
70. Sanders ME, Makgoba MW, Sharrow SO, et al. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma production. J Immunol 1988; 140:1401-1407.
71. Kitchens WH, Haridas D, Wagener ME, et al. Combined Costimulatory and Leukocyte Functional Antigen-1 Blockade Prevents Transplant Rejection Mediated by Heterologous Immune Memory Alloresponses. Transplantation 2012; 93:997-1005.
72. Kitchens WH, Haridas D, Wagener ME, et al. Integrin antagonists prevent costimulatory blockade-resistant transplant rejection by CD8-memory T cells. Am J Transplant 2012; 12:69-80.
73. Badell IR, Russell MC, Thompson PW, et al. LFA-1-specific therapy prolongs allograft survival in rhesus macaques. J Clin Invest 2010; 120:4520-4531.
74. Turgeon NA, Avila JG, Cano JA, et al. Experience with a novel efalizumabbased immunosuppressive regimen to facilitate single donor islet cell transplantation. Am J Transplant 2010; 10:2082-2091.
75. Reisman NM, Floyd TL, Wagener ME, et al. LFA-1 blockade induces effector and regulatory T-cell enrichment in lymph nodes and synergizes with CTLA-4Ig to inhibit effector function. Blood 2011; 118:5851-5861.
76. Bestard O, Cassis L, Cruzado JM, et al. Costimulatory blockade with mTor inhibition abrogates effector T-cell responses allowing regulatory T-cell survival in renal transplantation. Transpl Int 2011; 24:451-460.